Citeline Trialtrove subscriber accessing data of completed clinical trials.

After a year of decline in 2022, completed clinical trials were on the upswing again in 2023. According to Trialtrove, 4,295 industry-sponsored Phase I-Phase III/IV clinical trials either reached completed status or reported primary endpoints during 2023. This is a 10.7% increase over 2022.

Related resources

Infographic Banner for Pharma R&D Annual Review 2024 Supplement NAS Infograpic
MAY 09, 2024

Pharma Annual R&D Review 2024 Supplement Infographic: New Active Substances Launched During 2023

Highlights from the Pharma R&D Review 2024 Supplement, a look at new active substances (NASs), drugs launched onto the market for the first time, in 2024.

Q2 2024 Outlook Report
APR 08, 2024

Q2 2024 Outlook Report

Discover the catalysts, deals and likelihood of approval for 22 key drugs, devices and diagnostics expected to occur in Q2 2024.

Citeline subscribers accessing the 2023 Deal-Making Roundup white paper reported by Biomedtracker.
MAR 28, 2024
White paper

2023 Deal-making Roundup

An overview of alliance, M&A, and financing deal activity across the
worldwide biopharma, medical device, and in vitro diagnostics
industries in 2023